Mucoangin Johannisbeere (Ambroxol Hydrochloride)

Ambroxol stimulates surfactant production by type II pneumocytes and enhances ciliary beat frequency. This reduces the viscosity of airway secretions and improves mucociliary clearance, allowing patients to expectorate mucus more easily and relieve cough.

The appropriate dose is determined by the prescribing healthcare professional based on the patient’s age, severity of symptoms, and clinical response. Patients should follow the dosage instructions on the product label or those provided by their physician.

Safety data for Ambroxol in pregnancy and lactation are limited. It should only be used if clearly needed and after a risk‑benefit discussion with a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any required import documentation.

Compared with alternatives such as N‑acetylcysteine, Ambroxol not only reduces mucus viscosity but also stimulates surfactant production, which can improve cough efficiency. Its oral route and favorable safety profile make it a convenient option for many patients, though individual response may vary.

Store the product at ambient temperature below 25 °C, in its original packaging, and protect it from moisture and direct sunlight. Do not use if the packaging is damaged or if the product shows signs of degradation.

Mucoangin Johannisbeere is taken via the oral mucosa. The tablet or lozenge is placed in the mouth and allowed to dissolve completely, ensuring the active ingredient contacts the oropharyngeal mucosa before swallowing, as directed by the label or a healthcare professional.

Serious adverse reactions, although rare, include severe allergic responses such as rash, angioedema, anaphylaxis, hepatic enzyme elevations, eosinophilic pneumonia, and bronchospasm. Patients should seek immediate medical attention if they experience any signs of a severe reaction.

Individuals with a known hypersensitivity to Ambroxol or any excipients in the formulation should avoid the product. It is also contraindicated in patients with severe hepatic impairment or those taking medications that have a documented major interaction with Ambroxol.